title: Expression of aberrant CD markers in acute leukemia: a study of 100 cases with immunophenotyping by multiparameter flowcytometry.
abstract: BACKGROUND
  Acute leukemia is a heterogenous disease having diverse phenotypes. Immunophenotyping by flowcytometry is essential for diagnosis of myeloid and lymphoid subtypes. Aberrant phenotype incidence is controversial and dissimilar results have been reported by different groups.
  
  
  OBJECTIVE
  Purpose of the study was to determine the incidence of aberrant phenotypes in North East Indian patients with acute leukemia.
  
  
  METHODS
  We analysed a total of 100 cases (AML = 36, ALL = 61, MPAL = 3) by multiparametric flow cytometry using an acute panel of monoclonal antibodies (MoAbs). The MoAbs were selected to identify differentiation-associated antigens of both myeloid and lymphoid lineages.
  
  
  RESULTS
  Aberrant phenotypes were found in 21 (58.3%) cases of AML, 36 (59.2%) cases of B-ALL and 6 (66.7%) cases of T-ALL. CD7 was the most frequent lymphoid associated antigen found in 33% of AML cases while CD117 was the myeloid antigen most frequently detected in ALL (54%) cases. Aberrant expression of CD 117 is highly significant by Fischer's exact test (P< 0.0001).
  
  
  CONCLUSIONS
  We conclude that aberrant phenotypes are present in a great majority of acute leukemia patients of North East India. Future studies will be directed to correlate of these markers with prognosis and therapeutic response.
authors.affiliation: Department of Pathology, Dr. B. Borooah Cancer Institute, Guwahati, India.
authors.forename: Anupam
authors.initials: A
authors.lastname: Sarma
authors.affiliation: Department of Medical Oncology, Dr. B. Borooah Cancer Institute, Guwahati, India.
authors.forename: Munlima
authors.initials: M
authors.lastname: Hazarika
authors.affiliation: DBT Centre for Molecular Biology & Cancer Research, Dr. B. Borooah Cancer Institute, Guwahati, India.
authors.forename: Debabrata
authors.initials: D
authors.lastname: Das
authors.affiliation: DBT Centre for Molecular Biology & Cancer Research, Dr. B. Borooah Cancer Institute, Guwahati, India.
authors.forename: Avdhesh
authors.initials: A
authors.lastname: Kumar Rai
authors.affiliation: Department of Pathology, Dr. B. Borooah Cancer Institute, Guwahati, India.
authors.forename: Jagannath Dev
authors.initials: JD
authors.lastname: Sharma
authors.affiliation: Department of Medical Oncology, Dr. B. Borooah Cancer Institute, Guwahati, India.
authors.forename: Chidananda
authors.initials: C
authors.lastname: Bhuyan
authors.affiliation: Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute, Guwahati, India.
authors.forename: Amal Chandra
authors.initials: AC
authors.lastname: Kataki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology; D015703:Antigens, CD / Q000097:blood* / Q000276:immunology; D002648:Child; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007194:India; D007938:Leukemia / Q000097:blood* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD
keywords: Acute leukemia; CD marker; aberrant phenotype; flow cytometry